EYECHEQ

Point-of-Care Retinal & Vision Screening Infrastructure

600%	**98.7%**	**33%**	**3 min**
Screening Compliance Lift	**Image Gradability**	**Referable Condition Rate**	**Exam Time**
4% → 30% at Summa Health	*Taher 2026, n=454*	*Of screened diabetic patients*	*No eye doctor required on-site*

EyeCheq is a U.S.-based, physician-founded, tech-enabled screening company deploying FDA-cleared retinal imaging, autorefraction, and visual acuity stations across labs, retail, primary care, and FQHC settings — closing HEDIS diabetic-eye-exam care gaps at the point of care, with zero staff required and results returned within one business day.

SEED+ RAISE: $8–10M Priced Round • $4M Closed • Revenio Group / iCare (Nasdaq Helsinki: REG1V) — Strategic Anchor

EyeCheq Screening Station

National Deployment — Nine Channels Live or Advancing

Retail, health-system, laboratory, and payer channels spanning the U.S. — as of Q2 2026

1 Quest Diagnostics
7 sites live in Chicago (Aetna); 10 more across Florida this summer

2 VSP / iCare Health Solutions
550 MSOs across Florida; 2 sites advancing statewide rollout

3 Advocate Health / Atrium Health
2 sites live in North Carolina; 350+ PCP sites in discussion

4 Walmart (via 2020Now)
8 NY/PA sites approved, pending Walmart Legal clearance

5 JINS Eyewear
Live in Los Angeles; expansion talks toward 500 Japan locations

6 LabCorp
Mutual NDA signed; 5-site pilot under discussion

7 Conviva / CenterWell (Humana)
200+ FL PCP network; 2 sites targeted to close in Q3

8 Costco
2-location optical department pilot in active discussion

9 Kaiser Permanente
Vision Essentials pilot in active discussion

CLRA — Referral Coordination Infrastructure (Wholly-Owned EyeCheq Subsidiary)

Debuted nationally at the VisionSource Exchange (Nashville) • Ali Khoshnevis, OD — Chief Executive Officer • Connects patients from screening to definitive follow-up care across the OD–MD referral chain

Leadership & Strategic Position

A physician-founded team with a proven exit track record, backed by a strategic OEM anchor investor

LEADERSHIP

Rashid Taher, MD
Co-Founder & CEO
Vitreoretinal surgeon; cofounder, Pediatric Radiology of America (acq. Aris Teleradiology)

Ruwan Silva, MD, MBA
Chief Medical Officer
Professor, Stanford University School of Medicine

Ali Khoshnevis, OD
Co-Founder & Chief Strategy Officer; CEO, CLRA
Cofounder, PxSource (acq. RevolutionEHR) & Tesser Health (acq. ELMC)

Jordan Duggan
Chief Technology Officer
Prior product & development leadership at InspectionXpert and Virtru

Chris Grant
Chief Commercial Officer
Former EVP, Quest Diagnostics; former EVP, Kaiser Permanente

Aaron Tufankjian
EVP & Chief of Market Access and Growth
26+ years across Anthem, Cigna, UnitedHealthcare, Humana & Aetna

Jai Parekh, MD, MBA
Chief Innovation Officer
Former Chief Medical Officer, Allergan Eye Care

WHY NOW

CMS's CY2027 Final Rule (CMS-4212-F) eliminates chart review as a valid data source for the Eye Exam for Diabetic Patients (EED) Star measure, effective June 2026 — while retaining EED itself. Medicare Advantage plans now need scaled, verifiable point-of-care screening to protect Star ratings and risk-adjustment revenue. EyeCheq is purpose-built for this mandate.

STRATEGIC ANCHOR INVESTMENT

iCare Finland / Revenio Group (Nasdaq Helsinki: REG1V) — maker of the DRSplus retinal camera powering EyeCheq's stations — closed its strategic investment this quarter, deepening the OEM relationship and supply chain. John Floyd, iCare's VP of Global Sales, joined EyeCheq's Board of Directors, aligning technology, capital, and governance ahead of a targeted 2028 Series A.

Rashid Taher, MD | Co-Founder & CEO, EyeCheq, Inc. | Rashid@eyecheq.com | 786.223.3937 | Demo: vimeo.com/1004207420